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Purpose: The purpose of this study was to investigate the RBE in proton arc therapy and 
compare it to RBE in intensity modulated proton therapy plans. The use of RBE-models in 
treatment planning has the potential to reduce the physical dose needed for tumor control. 
Methods: In this project the FLUKA MC code was used together with a prototype optimizer 
to calculate and optimize RBE-weighted dose distribution for IMPT and PAT plans. A 
treatment planning system was used to construct the plans used in this study. The treatment 
plan information was exported from the TPS and converted to a format that could be used for 
FLUKA simulations and the prototype optimizer. Mathematical description of two RBE 
models were included in the biological optimization of the plans, namely the McNamara 
model and the Rørvik unweighted model. The different treatment plans consisted of one IMPT 
plan and one PAT plan, for a water phantom case and a patient case. The dose distributions 
and RBE distributions for the different cases were compared. In addition, a PAT plan with 
lower maximum proton energy was made, to investigate the possibility and effect of placing 
the highest RBE and LETd values inside the target volume. 
Results: Across the water phantom and patient cases, the dose homogeneity and dose 
gradients were increased with the proton arc therapy plans. The calculation of physical dose 
distribution for the variable RBE-optimized plans, showed lower physical dose to the PTV 
compared to plans optimized with RBE1.1 in all cases. For all cases the physical dose optimized 
with respect to the Rorvik unweighted model were lower than the physical dose optimized 
with respect to the McNamara model. 
Conclusion: Based on the results in this study the use proton arc therapy has the potential to 
increase dose homogeneity and improve dose gradients compared to intensity modulated 
proton therapy. The application of variable RBE-models in treatment planning has the 
potential to lower the physical dose to the target volume, thereby preventing potential over-
dosage of the tumor and surrounding healthy tissue. Significant differences were seen between 
the variable RBE-models. This gives rise to uncertainties, and therefore more research is 
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More than 34000 cancer cases were reported in Norway in 2019 [1]. Three of the main 
treatment modalities for cancer treatment are chemotherapy, surgery, and radiotherapy. About 
half of all cancer patients are eligible for radiotherapy at some stage during the course of their 
disease. The main goal of radiation therapy is to kill or sterilize tumor cells using ionizing 
radiation, while sparing the surrounding healthy tissue as much as possible.  
External beam radiation therapy can be separated in to two main categories: Photon therapy 
and particle therapy. Photon therapy uses highly energetic photons to irradiate cells, while 
particle therapy uses massive particle such as protons or carbon ions. Massive particles are, in 
general, more effective at killing cells than photon radiation. 
In recent years, the interest in proton beam therapy has spiked in Norway, as two proton centers 
are being built, one in Oslo and one in Bergen. Both centers plan to start treating patients with 
protons in 2024 [2]. 
1.1 A short history of radiation therapy 
In November 1895 Wilhelm Röntgen discovered X-rays. Already in January 1896 X-rays were 
used to treat a patient with breast cancer, although the lack of knowledge of biological effect 
and physical mechanisms was extensive. Röntgen’s discovery was followed by Becquerel’s 
report on the phenomenon of radioactivity and Curie’s discovery of radium. These discoveries 
sparked the start of the science of radiotherapy [3]. In the early 1900s the first high voltage X-
ray tubes were made, and dose fractionation was proposed, as opposed to delivering all the 
dose at the same time. These discoveries, along with others, helped develop radiotherapy and 
led to better cure rates and better sparing of healthy tissue. In the 1950s the first electron linear 
accelerators became clinical available [4]. This made it possible to treat more deep-seated 
tumors, and it led to greater skin sparing and improved disease-control rates [3].  
In 1946 Robert Wilson laid the groundwork for ion beam therapy with a paper proposing the 
use of protons and heavier ions for medical purposes [5]. The first clinical treatment using a 
proton beam was in Berkeley in 1954 [6]. In the following years, the use of protons for 
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radiotherapy became more widespread, and many proton therapy centers were built around 
the world. Treatments using heavier ions such as helium- and neon ions were first conducted 
in 1957 and 1975, respectively [7]. At the time treatment using protons and heavier ions was 
highly experimental, and it was done in physics laboratories [8]. The first hospital-based 
proton treatment facility was opened in 1990 in California USA [9]. The introduction of the 
CT scanner in the 1970s allowed treatment planning to shift from two- to three dimensions. In 
addition, CT-based systems allowed assessment of density variations in patient tissue. This 
increased the precision of dose planning, by reducing uncertainties tied to tissue heterogeneity. 
With CT-based planning and multileaf collimators (MLC), the latter was developed in the 
1990s, the treatment could be done by sculpting the dose in three dimensions to cover the 
target volumes and avoid organs at risk (OAR) as much as possible. 
In the 1990s and the 2000s new treatment methods, which further improved dose conformity 
and sparing of OARs, were introduced. The first commercial intensity modulated radiation 
therapy (IMRT) center was introduced in 1994 [10]. Followed by volumetric modulated arc 
therapy (VMAT) and adaptive radiotherapy (ART) in the 2000s. These new techniques made 
it possible to further customize treatment plans based on patients, locations, and tumor extents.  
1.2 Proton therapy 
One of the major advantages of using protons for radiation 
therapy, as compared to photons, is the differences in dose 
deposition, which is displayed in Figure 1.1. The dose 
distribution of photons is characterized by a short build up 
region, followed by an exponential dose falloff. This means 
that a considerable amount of healthy tissue will receive 
dose, especially for deep seated tumors. Because of the 
penetrating ability of photons, tissue behind the target will 
also receive dose. Comparably, the dose distribution of 
protons is characterized by a low dose region, followed by 
a dose increase and a sharp dose fall off. The high dose 
region of the dose deposition is called the Bragg peak, and 
Figure 1.1: Depth dose curves for photons 
(dashed lines), protons (solid line) and a 
dotted line representing a spread out Bragg 
peak for protons [11]. 
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it is located at the end of the proton range. Figure 1.1 also shows a spread-out Bragg peak 
(SOBP). The SOBP is made by using protons of many different energy layers. The sum of 
these protons dose curves results in a SOBP. 
The VMAT technique for photon therapy was first described in 1993. It involves continuous 
rotation of the gantry, in one or more arcs, around the patient during treatment. This differs 
from IMRT where the radiation beam is switched off between gantry movements, between 
different beam angles. This technique increases dose confinement to the tumor and reduces 
toxicity to healthy tissue compared to other photon delivery techniques, such as IMRT [12]. 
Traditionally proton therapy has been delivered using a small number of beam angles, and 
varying the energy of the protons. This is referred to as intensity modulated proton therapy 
(IMPT). However, the benefits of VMAT compared to other photon delivery techniques has 
cause interest in the possibility of arc delivery techniques for proton therapy. In 2016 the first 
delivery efficient proton arc therapy (PAT) technique was introduced [13], and in 2019 the 
first prototype of proton arc treatment delivery was introduced [14]. Similarly to VMAT the 
treatment is delivered with continuous gantry rotation in one or several arcs around the patient. 
Proton arc therapy has the potential to increase healthy tissue sparing, reduce range 
uncertainty, improve dose conformity, and improve dose gradients, compared to VMAT and 
IMPT [15, 16].  Figure 1.2 shows an illustration of the IMPT and PAT delivery techniques. 
 
Figure 1.2:Illustration of dose distributions for the intensity modulated 
proton therapy (IMPT) and proton arc therapy (PAT) delivery techniques. 
The arrows represent different beam angles [17]. 
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Proton therapy has in later years been established as an important modality, as it has several 
benefits compared to photon therapy. As mentioned, proton therapy offers better normal 
tissue sparing as well as very low dose deposition beyond the target volume. In addition, 
protons have an increased relative biological effectiveness (RBE) compared to photons. In 
clinical proton therapy a constant RBE of 1.1 is used, meaning that protons are ten percent 
more efficient at cell killing than photons. However, an increasing amount of experimental 
and clinical data show that RBE varies spatially within the patient, depending on factors 
such as tissue type, dose per treatment fraction and linear energy transfer (LET). 
In addition to the different dose distributions between photons and protons, the biological 
effects, that is their ability to kill or sterilize cells, differs due to the differences in particle 
interactions between photons and protons. To describe this difference, the relative biological 
effectiveness (RBE) was introduced. The RBE is defined as the ratio between the dose 
delivered by a reference radiation (normally photons) and protons [18]. To account for the 
difference in RBE a constant RBE-factor of 1.1 is used in clinical proton therapy, meaning 
that protons are assumed to be 10% more effective at cell killing than photons [19]. 
However, an increasing amount of experimental and clinical data show that RBE varies 
spatially within the patient, depending on factors such as tissue type, dose per treatment 
fraction and ionization density.  
1.3 Motivation 
The use of a constant RBE of 1.1 is therefore view as an oversimplification, which in principle 
can lead to both over- and underdosage of the tumor, as well as higher dosage to surrounding 
normal tissue. Therefore, many variable RBE-models, based on experimental data, have been 
developed for proton therapy. These variable RBE-models generally predict higher RBE 
values than 1.1, especially at the distal area of the Bragg-peak. The use of RBE  models in 
treatment planning and optimization could therefore increase the quality of treatment plans for 
proton therapy [20]. With the introduction of proton arc therapy, it is of interest to investigate 
the effects of variable RBE using this delivery technique. 
The objective of this study is therefore to create a system for simulating proton arc therapy 
plans and examine the dose distributions to patients from this. Variable RBE-models will be 
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used to re-optimize treatment plans, calculate dose distributions from these plans, and compare 
the distributions to doses calculated with the clinically used RBE of 1.1, and to doses from 









2. The Physics of particle therapy 
2.1 Proton interactions in matter 
In radiotherapy protons have three main ways of interacting with matter: They are deflected 
by Coulomb scattering with nuclei, lose kinetic energy due to inelastic interactions with atomic 
electrons and undergo nuclear interactions with nuclei [21]. Protons are called heavy charged 
particles, as they have a large rest mass compared to the rest mass of electrons. 
 
Figure 2.1: The three main interactions between protons and matter: (a) inelastic 
interactions with atomic electrons, (b) Coulomb-scattering with nuclei and (c) 
nuclear interactions [21]. 
2.1.1 Inelastic interactions with atomic electrons 
The primary source of proton energy loss is through inelastic interactions with atomic 
electrons. Protons will interact with atomic electrons either by excitation or ionization of the 
electrons, and through these reactions the protons lose energy [22]. The mass of a proton is far 
greater than the mass of an electron, therefore the proton will not deviate significantly from 
its trajectory through interactions with electrons. Most of the secondary electrons will travel a 
short distance from the point of interaction, and they will ionize and deposit energy. 






















Where dE is the energy loss over a small distance dx. The ratio dE/dx is called stopping power. 
The remaining variables are described in Table 2.1. 
Table 2.1: Description of Bethe-Bloch equation variables. 
Variable Description Variable Description 
𝑁𝑎 Avogadro’s number 𝐴 Atomic mass of the 
absorber 
𝑟𝑒 Electron radius 𝑧 Charge of the 
incident particle 
𝑚𝑒 Electron mass 𝛽 Relativistic velocity 
𝑐 Speed of light 𝑣 Speed of the 
incident particle 
𝜌 Density of the 
absorber 
𝑊𝑚𝑎𝑥 Maximum energy 
transfer from a 
single collision 
𝑍 Atomic number of 
the absorber 
𝛿 Density correction 
factor 
𝛾 Lorentz-factor 𝐼 Mean excitation 
potential 




The stopping power is inversely proportional to the proton velocity, which means that the 
protons will deposit most of their energy towards the end of their range. This results in a dose 
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distribution that increases with range, and towards the end of the proton path a Bragg peak, 
which will be explained in a later chapter. 
2.1.2 Coulomb scattering 
When protons pass close to nuclei, they are deflected due to the positive charged nuclei. 
Although each deflection is small, the sum of deflections is significant. Therefore, Coulomb 
scattering is accounted for in does calculations with treatment planning system [21]. The 
deflection is proportional to the incident particle’s charge, and inversely proportional to the 
particle’s velocity and atomic weight [24]. 
2.1.3 Inelastic nuclear interactions 
In addition to the two interactions mentioned above, protons can also undergo nuclear 
interactions with nuclei. When the distance between a proton and a nucleus is sufficiently 
small, the proton can interact with the nucleus. In these reactions the nucleus may emit protons, 
neutrons, gamma rays or ion clusters. The emitted particle(s) contribute to the dose to the 
patient. And although most of the particles will not travel far from the beam track, neutrons 
might, as they do not have charge. This might cause dose to be deposited outside the planning 
volume [25].  
2.2 Dosimetry and depth dose curves 
2.2.1 Absorbed dose 
The energy absorbed by matter from radiation is called absorbed dose, also referred to as 
physical dose. The definition of dose is defined as the energy deposited by ionizing radiation, 




      (2) 
The unit used for dose is Gray (Gy) in the SI system, and 1 Gy = 1 J/kg. It is important to note 
that the energy deposited by e.g. a proton beam is larger than the absorbed dose. As some of 
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the energy will be transferred to neutral secondary particles which can deposit dose outside of 
the volume of interest (eg. in the shielding of the treatment room) [27].  
2.2.2 Spread-out Bragg Peak 
Delivering a homogeneous dose to the whole target volume is important in clinical 
radiotherapy. ICRU recommends that the dose in the target volume should be no lower than 
95% of the prescribe, and no higher than 107% [28]. With protons it is possible to produce a 
uniform dose distribution to the target using only one beam angle. This is done by modulating 
the proton energies to make a spread-out Bragg peak (SOBP). An example of this can be seen 















2.3 Linear energy transfer 
The Bethe-Bloch equation describes how much energy proton lose per unit length. However, 
there is a difference between this quantity and the energy absorbed by the medium. To describe 
this Zirkle introduced a quantity called linear energy transfer (LET) [29]. LET is defined as 
the energy transferred from the charge particle per unit length, to the biological material close 







]    (3) 
Higher LET values results in more effective cell killing as compared to lower LET values [30]. 
For protons, the LET increases with decreasing particle speed, which results in the protons 
being most effective at cell killing in the last part of their tracks. This gives protons an 
advantage in radiotherapy compared to photons, as they deposit most of their energy at the 
end of their path. 
 




Most of the proton’s energy is lost in the interactions described by the Bethe-Bloch formula, 
and deposited locally. However, a portion of the energy is converted to delta rays or 
bremsstrahlung. Bremsstrahlung is electromagnetic radiation produced by the deceleration of 
a charged particle when it is deflected by another charged particle. In these cases, the energy 
is deposited further away from the particle track. The LET with an energy cut-off to account 
for high energy delta rays is called the restricted LET and it is denoted LETΔ. If no energy cut-
off of delta rays is imposed, we get what is called the unrestricted LET: 
𝐿𝐸𝑇∞ ≅ 𝑆𝑒𝑙      (4) 
In this case the LET is equal to the electronic stopping power, Sel.  
From the definition of LET, the dose-averaged LET (LETd) can be derived. LETd is a quantity 
that takes both dose and LET into consideration and it is therefore used when biological 
outcomes are studied [32]. When calculating LETd the dose contribution of each individual 








    (5) 
Where Sel is the electronic stopping power of of a charged particle with kinetic energy E and 












3.1 Biological impact of ionising radiation 
In radiotherapy the target in the cell is the DNA, 
as damage to the DNA is the main cause of 
biological effects from ionizing radiation [33]. 
Particles have two ways of interacting with 
biological matter: Through direct and indirect 
action. The first is when a particle ionizes atoms 
inside the target causing biological damage. This 
is most common for high-LET radiation such as 
low energy protons. The latter is when a particle 
ionizes other atoms close to the target, creating 
reactive molecules that cause biological damage.                                                      
Figure 3.1: Illustration of indirect and 
direct action of radiation [32]. 
The most common damages to DNA in radiotherapy are single strand breaks (SSB) and double 
strand breaks (DSB). DSB are harder for the cell to repair because both strands of the DNA 
are damaged, and the cell cannot use one strand as a template to repair the other. Therefore, 
DSB are more effective than SSB at cell killing [33]. Higher LET leads to more damage being 
done through DSB. This implies that protons will have a higher biological effect compared to 
photons, as a larger percentage of the damage is done through DSB. Specifically, towards the 
end of their range, as proton LET values increases with decreasing proton energy. 
3.2 The linear-quadratic model 
The linear-quadratic (LQ) model is a commonly applied model that describes radiobiological 
effects and cell death. The model describes the surviving fraction (S) of cells after the cells 
have been irradiated by a dose (D). It is given by [18]: 
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                                                          𝑆(𝐷) = 𝑒−𝛼𝐷−𝛽𝐷
2
      (6) 
The parameters α and β are tissue specific parameters and determine the shape of the cell 
survival curve. The parameters can be correlated to single and double track events. At low 
doses there will be few double track events, and the α will dominate, while the β will dominate 
at higher doses as the amount of double track events increase [18]. The α/β ratio gives the 
deposited dose where the contribution from the linear part and the quadratic part of the LQ 
model is equal, i.e. when 𝛼𝐷 = 𝛽𝐷2. 
3.3 Relative biological effectiveness - RBE 
The relative biological effectiveness (RBE) of protons is a measure the biological effect of 
protons compared to a reference radiation (X- or γ-rays)[19]. RBE is defined as [18]: 
   𝑅𝐵𝐸 =
𝑑𝑜𝑠𝑒 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
𝑑𝑜𝑠𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
    (7) 
In clinical proton therapy an RBE value of 1.1 is used (RBE1.1). However, many studies have 
shown this to be incorrect [19], and have shown that the RBE depends on several factors such 
as LET, tissue type, charge, biological endpoint, and dose. In many instances the RBE is higher 
than 1.1, especially in the distal part of the SOBP, where the LET is high [19]. Proton treatment 
plans can be optimized by applying an RBE-weighted dose (DRBE) to account for the difference 
in biological effectiveness between protons and photons. The RBE-weighted dose is also 
called the biological dose and it is defined as: 
                                               𝐷𝑅𝐵𝐸 = 𝑅𝐵𝐸 ∗ 𝐷                                            (8) 
where D is the physical dose. In proton therapy the ICRU recommends using the RBE-
weighted dose with units Gy(RBE) [34]. 
As mentioned, studies have shown that there is an increase in RBE in the distal part of the 
SOBP. This increase in RBE also causes a biological range extension and an increase in the 




As mentioned higher LET values results in more effective cell killing. Studies have shown 
that the RBE has a strong dependency on LET [19]. The relationship between RBE and LET 
can be seen in Figure 3.3. The figure also illustrates the relationship between RBE and dose 
levels, as the RBE decreases with less cell survival. Thus, the relationship between RBE and 
dose is inversely proportional. There is also a strong decrease in RBE for LET values higher 
than 100 KeV/µm. This is because of the overkill effect. For a cell to be killed enough energy 
has to be deposited into the DNA to produce a sufficient amount of DSB [18]. Very high LET 
values result in more energy being deposited into a cell than the energy needed to kill the cell. 
Thus, there is less likelihood per unit dose that other cells will be killed, which results in a 
decreased RBE. 
Figure 3.2: Illustration of the biological range extension. The blue line is the absorbed dose, 
the orange dashed line is the RBE-weighted dose using a constant RBE of 1.1 and the orange 





3.3.1 Biophysical RBE models 
Many biophysical RBE models have been developed to predict the RBE in proton therapy. 
Nearly all models predict that RBE varies spatially with respect to variations in dose and LET, 
and the models therefore do not support the assumption of a constant RBE used clinically. 
Most RBE models are based on the LQ-model. From the LQ model (equation 6) the 
relationship between the photon and proton dose at the same survival can be described as 
follows:  
 
Figure 3.3: The relationship between LET and RBE for different surviving fraction 







= 𝑆𝑥                                  (9) 
Where D is the dose, and all variables with subscript x represent photon radiation while the 





























𝐷2                         (10) 
Inserting the definition of the RBE (equation 7) into equation 10, gives the following 
expression for the RBE [35]:  























)   (11) 
Further, expressions for the extreme RBE at low and high doses can be found by evaluating 
the upper and lower physical dose limits [35]: 
𝑙𝑖𝑚
𝐷→0
𝑅𝐵𝐸 = 𝑅𝐵𝐸𝑚𝑎𝑥 =
𝛼
𝛼𝑥
     (12) 
𝑙𝑖𝑚
𝐷→∞
𝑅𝐵𝐸 = 𝑅𝐵𝐸𝑚𝑖𝑛 = √
𝛽
𝛽𝑥
    (13) 
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All LQ-based RBE models can be formulated using equation however they differ in the 





4. Treatment planning and delivery in proton therapy 
4.1 Treatment planning 
The aim of treatment planning is to optimize the dose distribution to a target volume, while 
minimizing the dose to surrounding healthy tissue and organs at risk. Treatment planning is 
done by using simulation software known as treatment planning systems (TPS). The TPS 
simulates the treatment delivery and is used to calculate dose plans for patients. 
In treatment planning there is a balance between risk and benefit. Planning aims to maximize 
the probability of curing the patient (tumor control probability) while minimizing the 
probability of negative side effects (normal tissue control probability) [27]. The tumor control 
probability depends on the dose delivered to the tumor, and the normal tissue control 
probability depends on dose delivered to normal tissue. The possibility of achieving good 
tumor control is illustrated in Figure 4.1, and is often referred to as the therapeutic window 
[37]. 
 
Figure 4.1: Illustration of dose response curves for tumor control probability and 
normal tissue control probability. The gap between the two curves represent the 




4.1.1 Image acquisition 
The first step in the treatment planning process is to acquire images of the patient that can be 
used for planning in the TPS. The most common medical imaging modalities are computed 
tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) 
and ultrasound (US). Although all these modalities have advantages and disadvantages, CT is 
most used for radiotherapy as it can acquire tissue density information [38].  
4.1.2 Anatomical volumes  
The next step in the treatment planning process is importing the CT images into a TPS and 
delineating volumes of interest. Medical doctors and physicist use the acquired images to 
define volumes inside the patient, such as the target volume and organs at risk (OAR) [39]. 
Two important volumes defined in this process is the gross target volume (GTV) and the 
clinical target volume (CTV). The GTV is defined by the visible tumor, while the CTV takes 
invisible tumor growth into account. Then patient movement uncertainties and dose delivery 
uncertainties is accounted for, to delineate a planning target volume (PTV) [27]. The OARs 
are typically normal tissues or organs with a high radiation sensitivity. Therefore, they are 
delineated, as they significantly influence the dose planning prosses. Similarly, as for the PTV 
a planning organ at risk volume is delineated (PRV), to assure a high probability of adequate 
sparing of the OARs. 
 





4.1.3 Dose planning 
After all relevant volumes have been delineated the dose planning process starts. Then 
planning aims are prescribed, i.e. dose requirements for the PTV and normal tissue constraints 
for the OARs. The planning aims are based on thorough evaluation of the patient as well as 
diagnostic studies and ontological concepts. The treatment planner uses the planning aims to 
find a basis for an acceptable compromise between the dose to the target and the OARs [27].  
4.1.4 Plan optimization 
In intensity modulated proton therapy (IMPT) inverse planning is typically used. With pencil 
beam scanning each pencil beam can be steered by magnets to conform dose in the transverse 
plane (see Section 4.2.1). This type of conformation is also achievable with photons through 
IMRT or VMAT. However, the Bragg peak gives an additional degree of freedom for protons 
because modulation along the beam axis is possible. With pencil beam scanning each beam is 
weighted and optimized separately [34]. The optimization process consists of iteratively 
generating and assessing many plans and choosing the best one. This is achieved by giving a 
computer constraints and objectives. Constraints cannot be broken, while objective are given 
weights relative to each other, and in some cases small violations of the objectives can be 
allowed. After the computer has calculated a plan, the plan is assessed by a treatment planner, 
who makes sure the results are satisfactory. If they are not the constraints and objectives can 
be changed, and the plan can be reoptimized. 
4.1.5 Plan assesment 
Several different methods are used to evaluate treatment plans. Dose levels are displayed both 
on 2D CT images of the patients, either as a dose color wash or isodose lines and dose volume 
histograms (DVH) are made. These graphical displays are compared to the constraints and 
objectives given in the optimization process. Although the CT images give an impression of 
how the dose is distributed, it can be difficult to assess a plan in terms of dose delivered to 
different clinical volumes from such images alone. Therefore, DVHs are used in conjunction 
with the images. DVHs provide a better way to compare plans than dose images, although the 
spatial information is lost in the DVHs. The loss of spatial information can be compensated 




There are a lot of factors that contribute to the uncertainties of dose delivery in proton therapy. 
Firstly, there are uncertainties tied to patient alignment and setup. External markings on the 
patient are used to realign the patient for treatment after imaging. The imaging should therefore 
be done in the same patient position as the treatment delivery. In addition, patients are often 
immobilized to reduce the uncertainty tied to patient movement. Tissue heterogeneities and 
CT conversion uncertainties contribute to range uncertainty. Because of the many factors 
contributing to treatment delivery uncertainties, regulatory bodies suggests an aim that the 
delivered dose should be within 2.5% of the prescribed dose [8].    
4.2 Treatment delivery 
4.2.1 Beam delivery techniques 
In proton therapy there are two main beam delivery techniques to deliver a homogeneous dose 
to the target, passive scattering, and active scattering. The latter is also called spot-scanning 
proton therapy, and it makes use of pencil beam scattering (PBS). PBS have advantages over 
passive scattering when it comes to optimizing dose to target volumes, and it is therefore 
implemented in all new proton therapy centers. With PBS dipole magnets are used to steer the 
proton beam in the horizontal and vertical direction. In addition, the energy of the beam is 
changed to irradiate different layers of the target (see Figure 4.3). 
 
 
Figure 4.3: Illustration of the pencil beam scanning technique [24]. 
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4.3 Proton arc therapy 
In radiation therapy and arc refers to a gantry rotation, either continuous or discontinuous, 
around the isocenter.  IMPT treatments are usually delivered using a small number of beam 
angles (1-5), and the beam is turned off while the gantry moves between the different angles. 
However, the concept of proton arc therapy (PAT) was first introduced in 1997 [40], to 
combine the unique dose deposition curve of protons and the benefits of  rotating beams. PAT 
is not practical for clinical application with passive scattering, due to the difficulty of changing 
beam specific compensators and range modulator during gantry rotation. However, the 
increasing adoption of the spot scanning technique makes PAT technically viable. 
Different delivery methods have been proposed for spot-scanning proton arc therapy, like 
multiple static fields [16], distal edge tracking [41], and single energy modulation [42]. The 
multiple static fields delivery method consists the use of many static fields and beam angles 
for treatment delivery, meaning that the beam is turned off during gantry rotation. In distal 
edge tracking, all Bragg peaks are placed at the edge of the target volume. Single energy 
modulation is based on using one or two energy layers for all proton beams. However, all these 
methods either cannot perform continuous rotation-delivery or fail to utilize the freedoms in 
the spot-scanning technique. Research is still being done on the topic of developing efficient 
delivery methods for PAT, in order to implement the technique clinically. 
The concept of proton arc therapy is becoming clinically available, with a recent 
demonstration of deliverability of a spot-scanning proton arc plan within clinical requirements. 
[14]. The dosimetric benefits of proton arc therapy has been demonstrated in several studies. 
PAT has been shown to reduce skin dose, reduce integral dose, increase plan robustness, and 
increase normal tissue sparing for both extra-, and intra-cranial tumor [43-45]. Studies also 
demonstrate reduced treatment times with PAT compared to both VMAT and IMPT [14, 43].  
4.4 Monte Carlo Simulations 
Monte Carlo simulations is widely accepted to be the best way to provide accurate dose 
calculations [46]. By randomly sampling the possible outcomes of different particle 
interactions and physical processes from probability distributions, the Monte Carlo method 
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can simulate real world particles on a particle-by-particle basis. The simulations also take 
tissue heterogeneities into account, by using information about material properties, such as 
atomic composition and electron density. Each interaction that occurs in the simulation 
determines the next step in the simulation. If secondary particles are created in interactions, 
they are tracked as well. The precision of the Monte Carlo simulations is dependent on the 
number of event (N) in the simulation, and the uncertainty is proportional to 1/√𝑁, where N 
is the number of particles. 
4.5 DICOM files 
The DICOM file format is the standard format for storing information in medical imaging. 
The DICOM files contain the information needed to execute simulations of radiotherapy, such 
as images of the patient, coordinates of regions of interest, particle energies, gantry angles, 
etc. The DICOM format also makes the exchange of data between different software simpler.  
The DICOM files consist of four different file types: DICOM CT images, DICOM RT 
structure set, DICOM RT plan and DICOM RT dose. The CT images are stored as multiple 
files, one for each planar slice of the patient. As mentioned, the CT images contain information 
about density, as well as information about pixel size and patient orientation. The RT structure 
set contains information about the different ROIs, such as the PTV, CTV, and OARs. The 
structure set defines the coordinates of all the structure, and this is useful for visual dose 
displays, and needed to calculate DVHs. The RT plan file contains geometric and dosimetric 
data, and specifies beam properties, such as beam angles, beam modifiers and isocenter 
position. The RT dose file contains the dose data calculated in the TPS, as well as information 
about scoring regions and the sizes of scoring grids.  
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5. Materials and methods 
This chapter will describe the process of simulating and re-optimizing treatment plans. An 
overview of the process can be seen in Figure 5.1. Descriptions of the scripts used in the 
process can be found in Appendix A. The first step of the process was to generate treatment 
plans using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, 
California US). In Eclipse the plans were optimized with a constant RBE of 1.1. The plans 
were exported and the information from the treatment plan was modified into a format that 
could be used as input for FLUKA. Then MC simulations were run in FLUKA, and the output 
of the simulation was used in conjunction with other files to run the optimizer. The optimizer 
modifies the weightings of each individual pencil beam with respect to variable RBE-models 
chosen by the user. Finally, a FLUKA simulation was run with the RBE-optimized plans to 
generate the optimized dose distributions. 
 
 
Figure 5.1: Flowchart showing the steps of the simulation and re-optimalization process. 




5.1.1 Eclipse treatment planning system 
The Varian Eclipse TPS was used in this project to make treatment plans for a water phantom 
case and a patient case. It is also used at Haukeland University Hospital. Eclipse lets the user 
create plans for various treatment modalities, including proton beam therapy. Plans exported 
from Eclipse are in the DICOM (Digital Imaging and Communications in Medicine) format.  
5.1.2 FLUKA 
In this project the FLUKA MC code[47-49] was used together with FLAIR [50](FLUKA 
advanced interface). The subroutines used with FLUKA in this project were the source and 
the fluscw routines. The source routine reads pencil beam information and converts the 
information so it can be understood by FLUKA. The fluscw routine enables scoring of 
biological parameters by choice. As the Eclipse TPS calculate dose to water, the same was 




 , where 𝜌 is the density of the material, this is set to the density of water 
(1g/cm3). The fluscw routine also includes a table containing 𝛼 and  𝛽 values, which is 
multiplied by 𝑓𝑙𝑢𝑒𝑛𝑐𝑒 ∗ 𝐿𝐸𝑇 to calculate biological variables needed for biological dose 
calculations.  
VOXEL files, that define the geometry of the simulations, are made in FLAIR. This is done 
by converting the Hounsfield units from CT images, imported in the DICOM file format, into 
material densities and material compositions [51]. After the plan information, the source and 
fluscw routines and the VOXEL file have been imported or made in FLUKA, simulations can 
be run. Then information about the simulations, such as dose data can be exported and further 
processed. In this project the data was processed and examined using several python scripts 
(described in Appendix A) as well as using the software program 3D Slicer (see 5.1.4). 
The statistical uncertainty of FLUKA simulations is dependent on the number of primaries 






Therefore, the simulations in this project were run with 5000 primaries per beamspot to ensure 
reasonably low uncertainties. 
5.1.3 Optimizer 
An optimizer was used in this project to optimize the treatment plans with respect to biological 
dose with variable RBE-models. The models used in this project are described in chapter 5.3. 
The optimizer uses information about the pencil beams, physical dose, the biological variable 
𝛼 and 𝛽, and a voxel file to calculate new weightings for each individual pencil beam, with 
respect to the chosen biological model. The cell-line for the biological models is manually 
imported into the optimizer. In this project an 𝛼𝛽 − 𝑟𝑎𝑡𝑖𝑜 of 2Gy was chosen for all treatment 
plans.  
5.1.4 3D Slicer 
3D Slicer is a software made for medical imaging and informatics. Slicer reads DICOM files 
and can be used to create 1D, 2D and 3D plots of dose distributions. In this project Slicer was 
used, together with the extension SlicerRT, for DVH calculations.  
5.2 Treatment plans 
Treatment plans were first made for a cylindrical PTV in water, before proceeding to patient 
plans. All treatment plans and the water phantom were made in the Eclipse TPS. 
5.2.1 Cylindrical PTV in water 
The water phantom geometry consists of a cylindrical water phantom with radius 10cm and 
height 10cm, and a PTV with radius 2 cm and height 10cm, placed in the center of the 
phantom. A cylindrical phantom was chosen because of its symmetrical properties. An 
illustration of the water phantom can be seen in Figure 5.2.  
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For this project three different treatment plans were 
made for the water phantom. For all water phantom 
plans the PTV was prescribed a homogeneous dose of 
2Gy(RBE) The first plan consists of two opposing 
proton fields, as seen in Figure 5.2.  
The second plan is a 360O arc plan consisting of 64 
fields, equally spread around the phantom. 
The third plan is also a 360O arc plan consisting of 64 
fields, however in this plan the highest energy layers of 
each beam have been removed. This was done as an 
attempt to shift the highest RBE-values from outside to 
inside the PTV, as the highest RBE-values can be found 
at the end of the proton range generally outside the PTV in clinical proton treatment plans. For 
all water phantom plans the PTV was prescribed a homogeneous dose of 2Gy(RBE). 
5.2.2 Patient plans 
Two patient plans are included in this study. The patient case is a brain germinoma case, where 
two separate plans were created and simulated. The first plan consists of two opposite proton 
fields and can be seen in Figure 5.3. This plan was made as a comparison to the proton arc 
treatment plan. 
The proton arc plan was made with two opposite 120O arcs, and the arc was constructed by 
having 8 fields on each side of the patient at different angles. The arc plan can be seen in  
Figure 5.4. Both plans were optimized to give a homogeneous dose of 54Gy(RBE) to the 
PTV, with 1.8Gy(RBE) per fraction, meaning 30 total fractions. 
 
 
Figure 5.2: Illustration of the water 
phantom. The green outline marks then 





 Figure 5.3: Patient plan with two opposite fields made in Eclipse TPS, where the 
figure was taken from. The purple outline represents the PTV. 
 
Figure 5.4: Patient proton arc plan. The plan was made in Eclipse TPS.                




In this project, two variable RBE-models were used: The model by McNamara et al. 






 for photons as input parameters.  




































𝐿𝐸𝑇𝑑              (15) 
Where 𝑝0−3 are fit parameters for the model. MCN then uses Matlab to fit the model to 
























𝐿𝐸𝑇𝑑        (16) 
 
The RORU model assumes a linear dependency between the RBE and LET. In addition, the 
RORU model assumes that 𝑅𝐵𝐸𝑚𝑖𝑛 = 1, due to other published models having found only 





and LET values [36]. The RBEmax for the 
RORU model is described by the following equation: 
















In this section the results from the FLUKA simulations will be displayed. This includes dose 
distributions, LETd and RBE-weigthed doses and RBE-distributions, for each phantom and 
patient plan. In addition, comparisons between the dose distributions for RBE1.1 and for the 
two models are displayed, as well as DVHs and dose metrics for each plan. Figures and tables 
displaying information about the results are placed together for the water phantom 2 fields 
case and water phantom arc case, as well as after the patient 2 fields case and patient arc case, 
to make comparing the results of IMPT and proton arc therapy easier.  
6.1 Water phantom 
6.1.1 Cylindrical PTV in water - 2 opposing fields 
Figure 6.1 shows the dose distribution on a plane through the middle of the PTV (marked as a 
red circle), for RBE1.1 as well as for the two variable RBE models used, McNamara and 
Rorvik. The plot shows that the dose-distribution is relatively homogenous for all models. 
However, the DVH in Figure 6.7 and the dose metrics in  
 
Table 6.1 show that the dose for both variable models were less homogenous than for RBE1.1. 
Although, the variable models predict less homogenous dose to the PTV, the mean doses 
predicted by RBE1.1, MCN and RORU (2.01Gy(RBE), 2.03Gy(RBE) and 2.03Gy(RBE) 
respectively)  are similar for all models. 
The DVH in Figure 6.7 also displays the corresponding physical doses for each biological 
model. The mean physical doses predicted for RBE1.1, MCN and RORU were 1.83 Gy(RBE), 
1.64 Gy(RBE) and 1.50 Gy (RBE) respectively. Meaning that both variable models predict 
lower physical doses than RBE1.1. 
From the dose metrics in Table 6.1it can be seen that the absolute and relative difference 
between the mean dose (column 2) and D2% (column 4) is higher for both variable RBE models 
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than for RBE1.1. Meaning that the variable models predict higher dose to be delivered to a 
small part of the PTV compared to the mean dose predicted.  
Figure 6.3 shows RBE distributions for the variable models, Figure 6.5 shows an LETd 
distribution and Table 6.2 shows RBE metrics for the PTV for each variable model. The figure 
shows that both models predict RBE values above 1.1 inside the PTV. The mean RBE 
predicted inside the PTV by MCN and RORU were 1.23 and 1.35 respectively. The figures 
also show that high LET values correspond with high RBE values, and that both the highest 
RBE and LET values are found outside the PTV. 
6.1.2 Cylindrical PTV in water - 360O arc plan  
Figure 6.2 shows the biological dose distributions for the 360O arc treatment plan. The figure 
shows that the PTV receives a reasonably homogenous dose of 2.0Gy(RBE) for all RBE 
models, and this is supported by the DVHs in Figure 6.8. This shows this shows that the 
optimizer is able to produce a homogeneous dose, also when applying RBE-models and 360O 
arcs. 
From the dose metrics in Table 6.1, as well as the DVH in Figure 6.8, it can be seen that the 
dose profiles for the three models are very similar. Both D95% and D2% are within 0.04Gy of 
the mean dose for each separate model. The dose metrics show that the mean doses to the PTV 
predicted by RBE1.1, MCN and RORU were 2.01Gy(RBE), 2.01Gy(RBE) and 1.99Gy(RBE) 
respectively. The DVH also display physical doses corresponding to each biological model. 
The physical doses corresponding to MCN and RORU are lower than the physical dose 
corresponding to RBE1.1. Physical doses predicted by RBE1.1, MCN and RORU are 
1.83Gy(RBE), 1.63Gy(RBE) and 1.45Gy(RBE), respectively. Illustrating hot the use of RBE 
models reduces the physical dose deposition in this case.  
Figure 6.4 shows RBE distributions for the McNamara and Rorvik models, Figure 6.6 shows 
an LETd distribution and Table 6.2 shows RBE metrics for the PTV for each model. Both the 
MCN and RORU models predict higher RBE-values for the entire PTV than RBE1.1. The mean 
RBE in the PTV for MCN and RORU were 1.23 and 1.35, respectively. The figures also show 
that high LET values correspond with high RBE values, and that both the highest RBE and 
LET values are found outside the PTV. Overall, the RORU model predicts slightly higher 
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RBE values than the MCN model. This is in agreement with previous work done by Rørvik, 
et al. [53]. 
 
 
Figure 6.1: RBE weighted dose distributions for the water phantom case with two 
opposing fields, for (a) RBE1.1 and for the biological models (b) MCN and (c) RORU 
in a plane through the center of the PTV. The PTV is marked with a red outline. The 
prescribed dose to the PTV is 2.0 Gy. 
 
 
Figure 6.2: RBE weighted dose distributions for the water phantom 360O arc case, 
for (a) RBE1.1 (b) MCN and (c) RORU in a plane through the center of the PTV. The 





Figure 6.3: RBE distributions for the water phantom case with two opposing fields, 
for (d) MCN and (e) RORU.. The dose cutoff was set to 0.2 Gy. 
 
 
Figure 6.4: RBE distribution for the water phantom 360O arc case, for (d) MCN and  





Figure 6.5: LETd distribution for the water phantom case with two opposing fields. 
The dose cutoff was set to 0.2Gy. 
 
Figure 6.6: LETd distribution for the water phantom 360
O arc case, for. The dose 




Figure 6.7: DVHs of the water phantom case with 2 opposing fields for the RBE1.1, 
MCN, RORU models and corresponding physical doses for each model. 
 
 
Figure 6.8: DVHs of the water phantom case with the 360O arc plan for the RBE1.1, 







Table 6.1: Dose metrics for the PTV in the water phantom case with two opposing 
fields (top) and the 360O arc (bottom). Metrics are reported for each of the 
biological models. The corresponding physical doses for each model are given in 
parenthesis.  D95% and D2% represent the dose delivered to 95% and 2% of the 
volume of the PTV respectively.  
Model Mean dose [Gy(RBE)] D95%[Gy(RBE)] D2%[Gy(RBE)] 
Opposing fields 
RBE1.1 2.01 (1.83) 1.95 (1.78) 2.07 (1.89) 
MCN 2.03 (1.64) 1.90 (1.53) 2.20 (1.78) 
RORU 2.03 (1.50) 1.91 (1.40) 2.21 (1.63) 
360O arc 
RBE1.1 2.01 (1.83) 1.98 (1.8) 2.05 (1.86) 
MCN 2.01 (1.63) 1.98 (1.60) 2.04 (1.66) 







Table 6.2: RBE metrics for the PTV in the water phantom case with two opposing 
fields (top) and the 360O arc (bottom). Metrics are reported for each of the variable 
RBE models. 
Model Mean RBE Min RBE Max RBE 
Opposing fields 
MCN 1.23 1.19 1.33 
RORU 1.35 1.27 1.52 
360O arc 
MCN 1.23 1.22 1.26 
RORU 1.35 1.32 1.40 
 
Table 6.3: LETd metrics for the PTV in the water phantom case with two opposing 
fields (top) and the 360O arc (bottom). 
 Mean LET Min LET Max LET  
Opposing fields 
LETd [keV/μm] 2.99 2.50 4.07 
360O arc 






6.2 Patient plans 
6.2.1 Patient plan - 2 opposing fields 
Figure 6.9 shows the biological dose distribution for RBE1.1 as well as the two variable RBE 
models used. All models give a reasonably homogenous dose of 54.0Gy(RBE). This is 
supported by both the DVH in Figure 6.15 and dose metrics in Table 6.4. The mean doses 
predicted by RBE1.1, MCN and RORU were 54.0Gy(RBE), 54.0Gy(RBE) and 53,8Gy(RBE) 
respectively, illustrating that the optimizer is able to create homogeneous dose with the 
prescribed dose to the PTV for all the models. 
 The DVH in Figure 6.15 shows that the dose profiles for all models are similar. For all models 
the difference between the mean dose and D95% are within 2Gy(RBE) and the difference 
between the D2% and the mean dose are within 3Gy(RBE). The DVH also shows physical dose 
profiles corresponding to each biological model. The mean physical doses for RBE1.1, MCN 
and RORU are 49.1Gy(RBE), 44.3Gy(RBE) and 40.9Gy(RBE), respectively. This means that 
both variable models predict lower physical doses than RBE1.1, as seen for both water phantom 
plans. 
Figure 6.11 shows the RBE distributions for both variable RBE models, Figure 6.13 shows 
the LETd distribution and Table 6.5 displays RBE metrics for the PTV for each variable RBE 
model. The mean RBE values predicted for the PTV were 1.22 and 1.31 for MCN and RORU 
respectively, which means that both variable models predict higher RBE-values for the PTV 
than RBE1.1, as could also be concluded from the reduced physical dose for these models. The 
figures also show that high LET values correspond with high RBE values, and that both the 







6.2.2 Patient plan - Two 120O opposing arcs 
Figure 6.10 shows the RBE weighted dose distributions for RBE1.1, and the MCN and RORU 
models. All models predict a reasonably homogenous dose to the PTV of 54 Gy(RBE). This 
is supported by the DVH in Figure 6.16 and the dose metrics in Table 6.4. The mean dose 
predicted by RBE1.1, MCN and RORU were 54.0 Gy(RBE), 54.2 Gy(RBE), and 54.1 
Gy(RBE), respectively. This shows that the optimizer is able to create acceptable treatmeant 
plans using all the applied RBE models, delivering the prescribed homogeneous dose to the 
PTV. The deviation between the mean dose and both D95% and D2% are within 2Gy(RBE) for 
all models. 
The DVH in Figure 6.16 also show physical doses corresponding to each biological model. 
The mean physical doses predicted by RBE1.1, MCN and RORU were 49.1 Gy(RBE), 44.5 
Gy(RBE), 41.2 Gy(RBE), respectively. Both variable RBE models predict lower physical dose 
to the PTV than RBE1.1. 
Figure 6.12 shows RBE distributions for the variable RBE models, Figure 6.14 shows a LETd 
distribution, and Table 6.5 displays RBE metrics for the PTV for each variable RBE model. 
Both models predict RBE values above 1.1 for the entire PTV. The mean RBE predicted by 
MCN and RORU for the PTV were 1.22 and 1.31, respectively.  The figures also show that 
high LET values correspond with high RBE values, and that both the highest RBE and LET 






Figure 6.9: RBE weighted fraction dose distributions on a plane through the center 
of the PTV for the patient case with two opposing fields, for (a) RBE1.1 and for the 
biological models (b) MCN and (c) RORU in a plane through the center of the PTV. 
The PTV is marked with a blue outline. The prescribed dose to the PTV is 54.0Gy. 
 
 
Figure 6.10: RBE weighted fraction dose distributions on a plane through the center 
of the PTV for the patient case with two opposite arcs, for (a) RBE1.1, (b) MCN and 







Figure 6.11: RBE distribution for the patient case with two opposing fields, for 
MCN (d) and RORU (e) and LETd distribution (f). The dose cut-off was set to 5Gy.  
 
Figure 6.12: RBE distributions for the patient case with two opposite arcs, for (d) 




Figure 6.13: LETd distribution for the patient case with two opposing fields. The 
dose cutoff is was to 5Gy 
 
Figure 6.14: LETd distribution for the patient case with two opposite arcs. The dose 




Figure 6.15: DVHs of the patient case with 2 opposing fields for the RBE1.1, 
McNamara, Rorvik models and corresponding physical doses for each model. 
 
 
Figure 6.16: DVHs of the water phantom case with 2 opposing arcs for the RBE1.1, 
McNamara, Rorvik models and corresponding physical doses for each model. 
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Table 6.4: Dose metrics for the PTV in the patient case with two opposing fields 
(top) and the two 120O opposing arcs plan (bottom). Metrics are reported for of the 
each biological models. The corresponding physical doses for each model are given 
in parenthesis. D95% and D2% represent the dose delivered to 95% and 2% of the 
volume of the PTV respectively. 
Model Mean dose [Gy(RBE)] D95%[Gy(RBE)] D2%[Gy(RBE)] 
Opposing fields 
RBE1.1 54.01 (49.09) 52.51 (47.72) 56.40 (51.26) 
MCN 53.95 (44.34) 52.15 (43.08) 56.32 (45.87) 
RORU 53.75 (40.90) 51.78 (39.73) 56.73 (42.35) 
Opposing 120O arcs 
RBE1.1 54.00 (49.09) 53.09 (48.27) 54.81 (49.83) 
MCN 54.16 (44.48) 53.43 (43.73) 55.43 (45.07) 









Table 6.5: RBE metrics for the PTV in the patient case with two opposing fields 
(top) and with two 120O opposing arcs (bottom). Metrics are reported for each of 
the variable RBE models. 
Model Mean RBE Min RBE Max RBE 
Opposing fields 
MCN 1.22 1.19 1.26 
RORU 1.31 1.27 1.39 
Opposing 120O arcs 
MCN 1.22 1.21 1.24 
RORU 1.31 1.28 1.36 
 
 
Table 6.6: LETd metrics for the PTV in the patient case with two opposing fields 
(top) and with two 120O opposing arcs (bottom). 
 Mean LET Min LET Max LET 
Opposing fields 
LETd [keV/μm] 2.50 2.16 3.55 
Opposing 120O arcs 






6.3 360O arc plan for the water phantom with lower 
maximum proton energy 
Figure 6.17 shows the biological dose distributions for the 360O arc water phantom arc plan, 
optimized for RBE1.1. Therefore, the MCN and RORU models predict higher doses to the PTV 
than RBE1.1. From the metrics in Table 6.7, the dose predicted by RBE1.1, MCN and RORU 
were 1.99 Gy(RBE), 2.35 Gy(RBE) and 2.60 Gy(RBE), respectively.  
The dose distribution, the dose metrics and the DVH in Figure 6.20, shows that the dose to 
the PTV is inhomogeneous compared to all previously presented treatment plans. For all 
biological the difference between the mean dose and D95% are greater than 0.1Gy(RBE), and 
the difference between D2% and the mean dose are greater than 0.25Gy. Both the optimization 
process in the TPS and the optimizer used provided inhomogeneous dose profiles for this plan.  
Figure 6.18 and Figure 6.19 shows the RBE distributions for each model and a LETd 
distribution for the 360O arc water phantom arc plan. These figures show that the highest RBE 
and LET values are located inside the PTV. From Table 6.8 the mean RBE in the PTV for 
MCN and RORU were 1.29 and 1.43, respectively. These RBE values for the PTV are higher 
than for all other presented treatment plans. Table 6.9 displays LETd metrics. The mean and 
max LETd for the PTV are 4.32 [keV/μm] and 4.85 [keV/μm], respectively. These values are 
higher than for all other presented treatment plans. Similar to all other presented treatment 










Figure 6.17: Dose distribution in a plane through the center of the PTV for (a) 
RBE1.1, (b) MCN and (c) RORU. The red outline marks the PTV. The prescribed 
dose is 2.0Gy. 
 
Figure 6.18: RBE distributions in a plane through the center of the PTV for (d) 




Figure 6.19: LETd distribution. The dose cut-off was set to 0.2Gy 
 






Table 6.7: Dose metrics for the PTV in the 360O water phantom arc case with lower 
maximum proton energy for each biological models. D95% and D2% represent the 
dose delivered to 95% and 2% of the volume of the PTV respectively. 
Model Mean dose [Gy(RBE)] D95% D2% 
RBE1.1 1.99 1.88 2.27 
MCN 2.35 2.21 2.67 
RORU 2.60 2.43 2.96 
 
Table 6.8: RBE metrics for the PTV in the 360O water phantom arc case with lower 
maximum proton energy for each variable RBE model. 
Model Mean RBE Min RBE Max RBE 
MCN 1.29 1.26 1.31 
RORU 1.43 1.38 1.47 
 
Table 6.9: LETd values for the PTV in the 360O water phantom arc case with 
reduced maximum proton energy 
 Mean LET Min LET Max LET 





In this project, a prototype optimizer has been used together with the FLUKA MC-code to re-
optimize IMPT and PAT treatment plans with respect to different RBE-models. In addition, a 
treatment plan with lower maximum proton energy was produced, as an attempt to shift the 
highest RBE values in to the PTV. The dose, RBE and LET distributions of each plan have 
been presented. The results indicate that the PTV achieved the prescribed dose of 2.0Gy(RBE) 
for the water phantom plans and 54.0Gy(RBE) for the patient plans, although the PTV in the 
water phantom plan with lower maximum energy received inhomogeneous dose. However, 
the water phantom case with lower maximum energy showed promising results in terms of 
placing the highest RBE and LETd values inside the PTV. 
7.1 PAT and IMPT comparison 
Compared to the 2 fields plan the arc plans show promising results for both the water phantom 
case and the patient case. For both cases the doses of the arc plans to the PTV were more 
homogenous than for the 2 fields plans, for RBE1.1, MCN and RORU. The homogeneity of the 
RBE and LET values inside the PTV were also greater for both arc plans than respective 2 
fields plans. The differences in dose homogeneity are largest for the RORU and MCN 
weigthed dose distributions for the water phantom and patient cases. The water phantom plans. 
For this case the arc plan reduced the spread of the MCN and RORU weigthed dose 
distribution by more than 50%. However, the dose homogeneity of the water phantom 2 fields 
case is significantly poorer than for the water phantom arc case and the patient case. A possible 
explanation for this, is that the 2 fields water phantom plan used significantly pencil beam 
spots, with larger spacing between each spot, than the three other cases. This might have an 
impact on the optimization process, as it could be easier for the optimizer to optimize plans 
with more beam spots inside the optimization volume.  
The arc plans also improved dose gradients, and reduced the areas receiving intermediate dose 
levels compared to the 2 fields plans, in both the phantom and patient cases. However, in the 
arc plans a larger area received low dose. Delivering low dose to large areas in patients might 
result in higher risks of secondary cancer. Toussaint, et al. [54] suggests that possible 
implication of large low dose areas on secondary cancer risk should be studied further. 
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7.2 RBE model dose difference 
For the four treatment plans that were optimized with respect to the MCN and RORU models, 
both the MCN and RORU models provided lower physical doses than RBE1.1, and the RORU 
model provided the lowest physical dose of the two variable models. The RORU model 
provided physical dose to the PTV, which was generally 19% lower than the physical dose 
provided from RBE1.1, while the MCN model was generally 10% lower. For the four treatment 
plans the mean RBE values for the PTV provided from the RORU model were 7-9% higher 
than the mean RBE values provided by MCN. The considerable difference between the RBE 
and RBE-weighted doses for RORU and MCN are similar to results produced by Rørvik et al. 
[53].  
The RBE and physical dose difference between the RORU and MCN models are not 
homogeneous and increase with increasing RBE-values. The RBE max values provided by 
RORU were 10-13% higher than the values provided by MCN. This leads to the physical doses 
being inhomogeneous, and the largest dose differences between RORU and MCN are found 
towards the distal end of the beams, where the highest RBE values are found.  
Overall, the results indicate that using RBE-models in the plan optimization process can result 
in lower physical dose, decreasing the risk of side effects, while delivering the prescribed 
biological dose to the target volume. However, the considerable variations between the 
different RBE models gives rise to uncertainty when applying RBE-models for clinical 
treatment planning. This uncertainty might lead to under dosage of the target volume, reducing 
the probability of successful treatment. For this reason, variable RBE-models should at the 
moment not be implemented in clinical treatment planning. This is supported by Paganetti et 
al. [55], suggesting that the clinical RBE of 1.1 is sufficient for now. Therefore, more research 
should be done in the field of RBE models to make the implementation of a variable RBE 
clinically possible, as using a variable RBE model in treatment planning has the potential to 
reduce physical dose delivered significantly. 
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7.3 The 360O water phantom arc plan with lower maximum 
proton energy 
The 360O water phantom arc plan with lower maximum proton energy showed promising 
results in placing the highest RBE and LET inside the PTV. However, the dose distributions 
for all biological models were inhomogeneous, delivering significantly higher dose to the 
center of the PTV than the edges. Both the TPS and the prototype optimizer provided 
inhomogeneous dose distribution for the plan. One of the possible explanations for the 
inhomogeneity is the way the plan was constructed in the TPS. The plan was constructed by 
removing the highest energy proton beam spots for each beam of the 360O water phantom arc 
plan. This is not ideal, and a method for constructing plans with lower-than-normal max proton 
energy should be developed. Another possible explanation for the inhomogeneous dose 
provided by the TPS and the optimizer is the high amount of pencil beams used in this plan. 
The size of the .dat file containing information about the pencil beams caused the optimizer to 
shut down when running biological optimizations of the plan. The high amount of pencil beam 
might also have cause problems for the optimization process in the TPS. 
The concept of placing the highest RBE and LETd values inside the target volume should be 
explored further, as the higher RBE inside the target will result in a reduction of physical dose 
needed for tumor control. This could also reduce side effects, as the high LET from the distal 
part of proton beams is a major concern for normal tissue damage in proton therapy. 
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8. Conclusion  
In this project proton arc therapy was explored. By using a combination of a commercial 
treatment planning system, custom made code, simulation code and a prototype dose 
optimizer, the dose, RBE and LET distributions from proton arc plans were studied and 
compared to IMPT plans.  
The results in this thesis show that proton arc therapy has the potential to increase dose 
homogeneity and improve dose gradients. The largest increases in dose homogeneity were 
seen for the variable RBE-weigthed doses. In addition, the results showed that the physical 
dose from the RBE-weighted models was reduced by 7 to 13% compared to RBE1.1. This result 
points out the importance of biological treatment optimization, as it has the potential to reduce 
physical dose without comprising tumor control. 
The results from the 360O water phantom arc plan with lower maximum proton energy, 
illustrates the possibility of placing the highest RBE and LETd values inside the target volume. 
However, the dose distributions for this plan were inhomogeneous, further development of 
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Appendix A Tables containing descriptions of steps 
in the method 
Table A.1, Table A.2 and Table A.3 contain descriptions of the steps in the method. 
Table A.1: Information about files and scripts used for initial FLUKA simulations 
Script/file Description 
Treatment plan from the TPS Contains CT-images, and information about 
pencil beam, ROIs and dose. Exported from the 
TPS in the DICOM-format 
Sort_dicom.py Converts information from the DICOM-files into 
input files for FLUKA 
Source.f Contains information about beam source 
Input file Input file for FLUKA 
Fluscw.f Contains information about beam weightings 
Voxel file Contains Information about the voxels in the 
phantom or patient, generated by FLUKA using 
CT images and data about materials 
Pencil beam information (datfile) Information about the different parameters for 








Table A.2: Information about files and scripts used for the optimization process, as 
well as FLUKA dose verification 
Script/file Description 
Create_files_for_optimizer.py Generates files needed to run the optimizer 
HU_changer.py Reads in DICOM files and generates information about 
chosen ROIs 
ROI and PTV information Dose information and information about constraits for each 
ROI, generated by HU_changer.py 
Optimizer C++ based optimizer, described in 5.1.3 
Reoptimized pencil beam 
information 
Information generated by the optimizer about the new 
weightings for each pencil beam 
make_reopt_datfile.py Generates a .dat file containing the new weightings for each 
pencil beam from the optimizer 
FLUKA simulation with 
reoptimized data. 
New simulation run in FLUKA using the .dat file created by 






Table A.3: Information about scripts and files used for extracting dose metrics and 
plotting dose data. 
Script/file Description 
convert_to_dicom.py Converts files generated from the FLUKA simulations into 
DICOM files 
3D Slicer Software program used to plot DVHs and display dose 
metrics 
plot_dicom.py Plots 2D dose distributions for a chosen DICOM file and CT 
slice. 
2D Plots 2D dose results generated by plot_dicom.py 
DVH Dose Volume Histograms generated by Slicer, and by python 
scripts for plotting DVHs 
 
 
  
 
